Search

Your search keyword '"Hoi, Alberta"' showing total 15 results
Start Over Author "Hoi, Alberta" Publisher wiley
15 results on '"Hoi, Alberta"'

1. Association of Modified Systemic Lupus Erythematosus Responder Index Attainment With Long‐Term Clinical Outcomes: A Five‐Year Prospective Study

Author

Connelly, Kathryn, primary, Kandane‐Rathnayake, Rangi, additional, Hoi, Alberta, additional, Louthrenoo, Worawit, additional, Hamijoyo, Laniyati, additional, Luo, Shue Fen, additional, Wu, Yeong‐Jian Jan, additional, Cho, Jiacai, additional, Lateef, Aisha, additional, Lau, CS, additional, Chen, Yi‐Hsing, additional, Navarra, Sandra, additional, Zamora, Leonid, additional, Li, Zhanguo, additional, An, Yuan, additional, Sockalingam, Sargunan, additional, Hao, Yanjie, additional, Zhang, Zhuoli, additional, Chan, Madelynn, additional, Katsumata, Yasuhiro, additional, Harigai, Masayoshi, additional, Oon, Shereen, additional, Bae, Sang‐Cheol, additional, O'Neill, Sean, additional, Gibson, Kathryn A., additional, Basnayake, BMDB, additional, Kikuchi, Jun, additional, Takeuchi, Tsutomu, additional, Ng, Kristine Pek Ling, additional, Tugnet, Nicola, additional, Kumar, Sunil, additional, Goldblatt, Fiona, additional, Law, Annie, additional, Tee, Michael, additional, Tee, Cherica, additional, Tanaka, Yoshiya, additional, Ohkubo, Naoaki, additional, Tan, Jin Yu, additional, Karyekar, Chetan S., additional, Nikpour, Mandana, additional, Golder, Vera, additional, and Morand, Eric F., additional

Published
2022
Full Text
View/download PDF

5. COVID‐19 infection in patients with systemic lupus erythematosus: Data from the Asia Pacific Lupus Collaboration

Author

Cho, Jiacai, primary, Kandane‐Rathnayake, Rangi, additional, Louthrenoo, Worawit, additional, Hoi, Alberta, additional, Golder, Vera, additional, Chen, Yi‐Hsing, additional, Luo, Shue Fen, additional, Wu, Yeong‐Jian Jan, additional, Hamijoyo, Laniyati, additional, Lau, Chak Sing, additional, Navarra, Sandra, additional, Zamora, Leonid, additional, Tee, Michael, additional, Flora, Angelito, additional, Li, Zhan‐Guo, additional, An, Yuan, additional, Sockalingam, Sargunan, additional, Katsumata, Yasuhiro, additional, Harigai, Masayoshi, additional, Hao, Yanjie, additional, Zhang, Zhuoli, additional, Kikuchi, Jun, additional, Takeuchi, Tsutomu, additional, Basnayake, Duminda, additional, Goldblatt, Fiona, additional, Chan, Madelynn, additional, Ng, Kristine Pek Ling, additional, Bae, Sang‐Cheol, additional, Oon, Shereen, additional, O’Neill, Sean, additional, Gibson, Kathy, additional, Kumar, Sunil, additional, Law, Annie Hui Nee, additional, Tugnet, Nicola, additional, Tanaka, Yoshiya, additional, Nikpour, Mandy, additional, Morand, Eric, additional, and Lateef, Aisha, additional

Published
2020
Full Text
View/download PDF

9. Development of the Asia Pacific Lupus Collaboration cohort

Author

Kandane‐Rathnayake, Rangi, primary, Golder, Vera, additional, Louthrenoo, Worawit, additional, Luo, Shue‐Fen, additional, Jan Wu, Yeong‐Jian, additional, Li, Zhanguo, additional, An, Yuan, additional, Lateef, Aisha, additional, Sockalingam, Sargunan, additional, Navarra, Sandra V., additional, Zamora, Leonid, additional, Hamijoyo, Laniyati, additional, Katsumata, Yasuhiro, additional, Harigai, Masayoshi, additional, Chan, Madelynn, additional, O’Neill, Sean, additional, Goldblatt, Fiona, additional, Hao, Yanjie, additional, Zhang, Zhuoli, additional, Al‐Saleh, Jamal, additional, Khamashta, Munther, additional, Takeuchi, Tsutomu, additional, Tanaka, Yoshiya, additional, Bae, Sang‐Cheol, additional, Lau, Chak Sing, additional, Hoi, Alberta, additional, Nikpour, Mandana, additional, and Morand, Eric F., additional

Published
2018
Full Text
View/download PDF

15. Association of Modified Systemic Lupus Erythematosus Responder Index Attainment With Long-Term Clinical Outcomes: A Five-Year Prospective Study.

Author

Connelly K, Kandane-Rathnayake R, Hoi A, Louthrenoo W, Hamijoyo L, Luo SF, Wu YJ, Cho J, Lateef A, Lau CS, Chen YH, Navarra S, Zamora L, Li Z, An Y, Sockalingam S, Hao Y, Zhang Z, Chan M, Katsumata Y, Harigai M, Oon S, Bae SC, O'Neill S, Gibson KA, Basnayake B, Kikuchi J, Takeuchi T, Ng KPL, Tugnet N, Kumar S, Goldblatt F, Law A, Tee M, Tee C, Tanaka Y, Ohkubo N, Tan JY, Karyekar CS, Nikpour M, Golder V, and Morand EF

Subjects
Humans, Prospective Studies, Prednisolone therapeutic use, Glucocorticoids therapeutic use, Odds Ratio, Lupus Erythematosus, Systemic drug therapy
Abstract

Objective: In trials of systemic lupus erythematosus (SLE), the SLE Responder Index (SRI) is the most commonly used primary efficacy end point but has limited validation against long-term outcomes. We aimed to investigate associations of attainment of a modified version of the SRI (mSRI) with key clinical outcomes in SLE patients with up to 5 years of follow-up., Methods: We used data from a large multicenter, longitudinal SLE cohort in which patients received standard of care. The first visit with active disease (defined as SLE Disease Activity Index 2000 [SLEDAI-2K] score ≥6) was designated as baseline, and mSRI attainment (defined as a reduction in SLEDAI-2K ≥4 points with no worsening in physician global assessment ≥0.3 points) was determined at annual intervals from baseline up to 5 years. Associations between mSRI attainment and outcomes including disease activity, glucocorticoid dose, flare, damage accrual, Lupus Low Disease Activity State (LLDAS), and remission were studied., Results: We included 2,060 patients, with a median baseline SLEDAI-2K score of 8. An mSRI response was attained by 56% of patients at 1 year, with similar responder rates seen at subsequent annual time points. Compared to nonresponders, mSRI responders had significantly lower disease activity and prednisolone dose and higher proportions of LLDAS and remission attainment at each year, and less damage accrual at years 2 and 3. Furthermore, mSRI responder status at 1 year predicted clinical benefit at subsequent years across most outcomes, including damage accrual (odds ratio [OR] range 0.58-0.69, P < 0.05 for damage accrual ORs at all time points)., Conclusion: In SLE patients with active disease receiving standard of care, mSRI attainment predicts favorable outcomes over long-term follow-up, supporting the clinical meaningfulness of SRI attainment as an SLE trial end point., (© 2022 The Authors. Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results